Lilly has set a price of $32,000 per year for Kisunla, which is higher than the top-line price of $26,500 for Leqembi. However, according to the company, it could reduce the overall cost of treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback